The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000026" target="_blank" >RIV/00064190:_____/19:N0000026 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/19:00112440 RIV/00216208:11110/19:10398517 RIV/00216208:11140/19:10398517 RIV/00669806:_____/19:10398517 RIV/00209805:_____/19:00078311
Result on the web
<a href="http://dx.doi.org/10.21873/anticanres.13761" target="_blank" >http://dx.doi.org/10.21873/anticanres.13761</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.13761" target="_blank" >10.21873/anticanres.13761</a>
Alternative languages
Result language
angličtina
Original language name
The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents
Original language description
Background/Aim: The aim of our study was to assess the predictive role of primary tumour sidedness (PTS) in patients with metastatic colorectal cancer (mCRC) harbouring wild-type RAS and treated with targeted agents. Patients and Methods: The cohort included 178 patients treated with first-line chemotherapy plus cetuximab, panitumumab or bevacizumab. Results: We observed longer progression-free survival (PFS) and overall survival (OS) in patients with left-sided (L-CRC) compared to right-sided tumours (R-CRC) treated with anti-EGFR mAbs (p=0.0033 and p=0.0037), while there was no difference in patients treated with bevacizumab (p=0.076 and p=0.56). Finally, we observed longer PFS and OS in patients with L-CRC treated with anti-EGFR mAbs and those with R-CRC treated with bevacizumab compared to the reverse combination (p=0.0002 and p=0.011). Conclusion: PTS is a predictive factor for anti-EGFR mAbs, not for bevacizumab. Superior survival was observed when anti-EGFR mAbs were used for L-CRC and bevacizumab for R-CRC.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/LO1503" target="_blank" >LO1503: BIOMEDIC</a><br>
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ANTICANCER RESEARCH
ISSN
0250-7005
e-ISSN
1791-7530
Volume of the periodical
39
Issue of the periodical within the volume
10
Country of publishing house
GR - GREECE
Number of pages
8
Pages from-to
5645-5652
UT code for WoS article
000488512600042
EID of the result in the Scopus database
2-s2.0-85072774745